机构：资金高低切换迹象加强，生物医药ETF（159859）昨日获净申购3800万份，创新药ETF天弘（517380）本周获超3700万元资金净流入

Group 1 - The biopharmaceutical ETF (159859) experienced a slight decline of 0.7% as of the report date, with a trading volume exceeding 600 million yuan, making it the top performer among its peers [1] - The ETF has seen a net inflow of over 39 million yuan in the past two days, with a net subscription of 38 million units on August 27, bringing its total circulation to 7.141 billion units [1] - The ETF closely tracks the National Index of Biopharmaceuticals (399441.SZ), covering various sectors including innovative drugs, CXO, vaccines, and blood products, and is noted for its size and liquidity [1] Group 2 - The Tianhong innovative drug ETF (517380) is the largest in the market, covering both A-shares and Hong Kong stocks, and is the only ETF tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index [2] - The upcoming 2025 World Lung Cancer Conference (WCLC) in Barcelona is expected to showcase over 40 Chinese research projects, highlighting the importance of academic conferences as catalysts for the innovative drug sector [2][3] - The overall outlook for the innovative drug sector is positive, with expectations of improved fundamentals and potential profitability by 2026, alongside a hot market for overseas licensing and business development transactions [3]